Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Advances in Hematology|April 27, 2012
Novel therapies for aggressive B-cell lymphomaKenneth A Foon, Kenichi Takeshita, Pier L Zinzani
Immunotherapy|March 24, 2018
Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphomaMahsa Eskian, MirHojjat Khorasanizadeh, Pier L Zinzani, et al.
Anti-Cancer Drugs|April 25, 2003
Aggressive lymphoma: improving treatment outcome with rituximabBertrand Coiffier, Michael Pfreundschuh, Rolf Stahel, et al.
Leukemia & Lymphoma|October 24, 2024
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphomaCatherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, et al.
Leukemia & Lymphoma|June 19, 2004
Pathobiology of primary mediastinal B-cell lymphomaStefano A Pileri, Pier L Zinzani, Gianluca Gaidano, et al.
Italian Journal of Dermatology and Venereology|March 5, 2025
Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in ItalyMarco Ardigò, Leonardo Flenghi, Adalberto Ibatici, et al.
Cancer|April 16, 2011
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotypeFrancisco J Hernandez-Ilizaliturri, George Deeb, Pier L Zinzani, et al.
British Journal of Haematology|June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological originMyron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Advances in Therapy|January 21, 2023
Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi StudySridhar Chaganti, Arie Barlev, Sophie Caillard, et al.
Cancer|September 17, 2004
The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi, Chiara Broglia, Giuseppe Di Giulio, et al.
Pageof 3